Aliskiren - Noden Pharma

Drug Profile

Aliskiren - Noden Pharma

Alternative Names: Aliskiren fumarate; Aliskiren hemi-fumarate; CGP 60536B; Enviage; Rasilez; Rasilles; Riprazo; SPP 100; SPP 100B; Sprimeo; Tekturna

Latest Information Update: 11 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Novartis; Ohio State University
  • Class Amides; Antihypertensives; Fumarates; Small molecules
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension
  • Phase III Chronic heart failure
  • Discontinued Acute heart failure; Atherosclerosis; Diabetic macular oedema; Diabetic nephropathies; Kidney disorders; Myocardial infarction

Most Recent Events

  • 15 Nov 2017 Registered for Hypertension (In adolescents, In children) in USA (PO,pellets)
  • 12 Nov 2016 Interim efficacy data from a phase III ASTRONAUT trial in Acute heart failure (Adjunctive treatment) presented at the 89th Annual Scientific Sessions of the American Heart Association (AHA-2016)
  • 06 Jul 2016 Novartis has patent protection for aliskiren in USA and in the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top